Action of MK_7264 -Gefapixant- at human P2X3 and P2X2 and 3 receptors and in vivo efficacy in models of sensitisation
Send a publication request
close

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.




Authors
D Richards, JR Gever, AP Ford, SJ Fountain


Lab
Biomedical Research Centre, School of Biological Sciences, University of East Anglia, Norwich, UK

Journal
British Journal of Pharmacology

Abstract
The P2X3 receptor is an ATP_gated ion channel expressed by sensory afferent neurons and is used as a target to treat chronic sensitisation conditions. The first_in_class, selective P2X3 and P2X2/3 receptor antagonist, the diaminopyrimidine MK_7264 (gefapixant), has progressed to Phase III trials for refractory or unexplained chronic cough. We used patch clamp to elucidate the pharmacology and kinetics of MK_7264 and rat models of hypersensitivity and hyperalgesia to test its efficacy on these conditions.

BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)

Related products

Share this content